Supernus Pharmaceuticals Inc/ US8684591089 /
2024-07-26 10:00:00 PM | Chg. +0.0700 | Volume | Bid10:09:51 AM | Ask10:09:51 AM | High | Low |
---|---|---|---|---|---|---|
30.7500USD | +0.23% | 353,448 Turnover: 7.55 mill. |
12.3700Bid Size: 100 | 32.0000Ask Size: 100 | 31.4400 | 30.3100 |
GlobeNewswire
05-30
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
05-23
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epile...
GlobeNewswire
05-21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
05-12
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
05-09
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa St...
GlobeNewswire
05-02
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
04-24
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call o...
GlobeNewswire
04-24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmac...
GlobeNewswire
02-13
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Co...
GlobeNewswire
2023-11-02
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
GlobeNewswire
2023-10-25
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call o...
GlobeNewswire
2023-10-16
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journe...
GlobeNewswire
2023-10-10
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director